IBA Partners with the University of Pennsylvania Health System
IBA (Ion Beam Applications S.A., EURONEXT), a frontrunner in particle accelerator technology and proton therapy solutions for cancer treatment, has announced a noteworthy agreement. This partnership will see the installation of two ProteusONE compact proton therapy systems at a major medical center, reinforcing the enduring commitment and long-standing relationship between IBA and the University of Pennsylvania.
Details of the Agreement
The recently signed Memorandum of Understanding paves the way for the installation of the ProteusONE systems at the Penn Presbyterian Medical Center. A final contract is expected to be signed shortly, marking a significant step in the strategic expansion of proton therapy services. This agreement is crucial as the medical facility aims to improve its treatment capabilities and operational efficiency.
Enhanced Clinical Availability
The two ProteusONE systems will be positioned side by side, a strategic choice designed to optimize patient treatment efficiency while ensuring clinical availability. This innovative configuration underscores IBA’s dedication to advancing cancer treatment technologies. With the launch of proton therapy treatments projected for 2027, this partnership is set to greatly enhance patient care.
Long-Standing Collaboration
Since 2010, the University of Pennsylvania has been an essential partner for IBA, effectively utilizing the ProteusPLUS system at the Roberts Proton Therapy Center. This new agreement further strengthens their collaborative efforts, particularly in the pioneering field of Flash irradiation—an advanced technique in proton therapy.
Insights from Leadership
Olivier Legrain, CEO of IBA, shared his enthusiasm about the ongoing collaboration: "We are delighted to continue and deepen our long-standing partnership with the University of Pennsylvania as they expand their proton therapy services. They are among the leading institutions globally in the field of proton therapy." He highlighted the significance of trust in fostering innovation between IBA and the university.
University's Commitment to Advanced Cancer Therapy
Prof. James M. Metz, a prominent figure in Radiation Oncology, expressed his excitement regarding the partnership. He remarked, "We are eager to advance our proton therapy strategic plan by integrating two IBA single room solutions at Penn Presbyterian Medical Center. This initiative is a vital part of our efforts to broaden proton therapy services across the region using cutting-edge technology." Their shared mission focuses on enhancing access to advanced cancer therapies.
About IBA
Founded in Louvain-La-Neuve, Belgium, IBA is recognized as a global leader in particle accelerator technology, particularly within the proton therapy sector. The company also excels in industrial sterilization, radiopharmaceuticals, and dosimetry. With around 2,000 employees worldwide, IBA is renowned for its commitment to social and environmental performance and is proud to be a certified B Corporation.
Financial Notes
Investors can find IBA listed on the pan-European stock exchange EURONEXT under the ticker IBAB. This reflects its strong position within the market and highlights the growth potential this partnership represents, not only for IBA but also for advancements in cancer treatment overall.
Frequently Asked Questions
What is the purpose of the agreement between IBA and the University of Pennsylvania?
The agreement is centered on the installation of two ProteusONE proton therapy systems to enhance cancer treatment capabilities at the Penn Presbyterian Medical Center.
When are proton therapy treatments expected to begin?
Proton therapy treatments are projected to start in 2027 at the Penn Presbyterian Medical Center.
What are ProteusONE systems?
ProteusONE systems are compact proton therapy solutions designed to enhance clinical availability and efficiency in patient cancer treatments.
What role does IBA play in the proton therapy sector?
IBA is recognized as a global leader in proton therapy solutions, providing advanced technology and services that are essential for effective cancer treatment.
How long has the University of Pennsylvania been working with IBA?
The University of Pennsylvania has been collaborating with IBA since 2010, using various proton therapy solutions to treat patients.
